Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation.

Drug Discov Today

Division of Cell Biology and Immunology, Biomedical Parasitology and Translational-immunology Lab, CSIR-Institute of Microbial Technology (IMTECH), Sec-39A, Chandigarh-160036, India; Academy of Scientific and Innovation Research (AcSIR), Ghaziabad 201002, India. Electronic address: rajeevtyagi@imtec

Published: August 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Rheumatoid arthritis (RA) is an inflammatory, autoimmune and connective-tissue arthropathy. The methotrexate (MTX) and aceclofenac (ACL) combination drug regimen is known to regulate the immunological pathways. Also, RA-elicited inflammation is decreased by the combination drug treatment. ACL and MTX combination treatment has been shown to regulate the signaling pathway controlled by NF-κB and FOXO1. The present manuscript reviews the importance of the combination drug regimen to treat and/or manage RA. The combination drug regimen could affect the Th1/Th17 axis to switch the balance toward the immunoregulatory (Th1) phenotype for establishing immune homeostasis. In conclusion, we propose the study of the immunological signaling pathways in experimental humanized RA mice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2023.103671DOI Listing

Publication Analysis

Top Keywords

combination drug
16
drug regimen
12
th1/th17 axis
8
combination
6
aceclofenac methotrexate
4
methotrexate combination
4
combination therapy
4
therapy influence
4
influence th1/th17
4
axis modulate
4

Similar Publications

The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.

View Article and Find Full Text PDF

Microbial contamination of absorbable collagen membranes used in guided bone regeneration (GBR) may compromise healing outcomes. This study aimed to investigate whether the minimum inhibitory concentration (MIC) of hydrogen peroxide (HO) can improve the antibacterial effect of indocyanine green (ICG)-mediated antimicrobial photodynamic therapy (PDT) on absorbable collagen membranes while reducing the need for high HO concentrations. A laboratory-based model was developed using Streptococcus sanguinis and Staphylococcus aureus.

View Article and Find Full Text PDF

[Vitiligo].

Ned Tijdschr Geneeskd

September 2025

Amsterdam UMC, Nederlands Instituut voor Pigmentstoornissen (SNIP), Amsterdam.

Vitiligo is a chronic skin disease characterized by white patches caused by the destruction of melanocytes. The most well-known variant is non-segmental vitiligo, where patches are symmetrically distributed across the entire body, with alternating periods of stability and progression. The white patches arise due to an autoimmune reaction in which cytotoxic T-cells attack the melanocytes.

View Article and Find Full Text PDF

Enterotoxigenic (ETEC), a leading cause of diarrhea, is defined by heat-stable (ST) and/or heat-labile (LT) toxins and associated colonization factors (CFs). However, there is still a knowledge gap in understanding ETEC's evolution, particularly in endemic regions like Bangladesh. This study investigates the genomic attributes contributing to the rise of ETEC-associated diarrhea in Bangladesh during 2022-2023.

View Article and Find Full Text PDF

Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the affected population projected to reach 270 million by 2045. Our study analyzed 2 434 interventional trials registered between 2007 and 2024 in the Informa Pharma Intelligence database and found that anti-VEGF agents dominate the therapeutic landscape-bevacizumab represents 24.0 % of studies, ranibizumab 15.

View Article and Find Full Text PDF